Trials / Active Not Recruiting
Active Not RecruitingNCT03603951
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
A Phase 1 Study to Characterize Safety, Tolerance, Pharmacokinetics and Efficacy of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 272 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 multicenter, single-arm, open-label, dose escalation and dose expansion study of enhancer of zeste homolog 2 (EZH2 ) inhibitor SHR2554. This study will assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of SHR2554 in participants with relapsed or refractory mature lymphoid neoplasms in part I, and the the efficacy in PTCL patients will be studied in Part II.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR2554 | SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2. |
Timeline
- Start date
- 2018-08-14
- Primary completion
- 2026-02-14
- Completion
- 2026-08-14
- First posted
- 2018-07-27
- Last updated
- 2024-10-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03603951. Inclusion in this directory is not an endorsement.